Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0001288

Salbutamol sulfate for system suitability

Name: Salbutamol sulfate for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Salbutamol hemisulfate salt, α₁-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt, Albuterol sulfate

Faça loginpara ver os preços organizacionais e de contrato

Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):

C₁₃H₂₁NO₃ · 0.5H₂SO₄

Número CAS:

51022-70-9

Peso molecular:

288.35

Número MDL:

MFCD00055200

Código UNSPSC:

41116107

ID de substância PubChem:

329831344

NACRES:

NA.24

Produtos recomendados

Slide 1 of 10

1 of 10

Y0001186

Salbutamol impurity J

BP302

Salbutamol sulfate

S0150000

Salbutamol sulfate

Supelco

PHR1053

Albuterol sulfate

BP704

Salbutamol ketone impurity

Y0002386

Salbutamol for peak identification

Y0000034

Salbutamol impurity G

S0100000

Salbutamol

Supelco

PHR1960

Salbutamol Impurity D

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate

grau

pharmaceutical primary standard

família API

albuterol, salbutamol

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

chave InChI

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Informações sobre genes

human ... ADRB2(154)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto

Descrição

Preços

1012644

1012655

1012689

BP451

Salbutamol, British Pharmacopoeia (BP) Reference Standard

BP302

Salbutamol sulfate, British Pharmacopoeia (BP) Reference Standard

PHR1960

Salbutamol Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2040

PHR1961

Salbutamol Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1962

Salbutamol impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

BP712

Salbutamol aldehyde impurity, British Pharmacopoeia (BP) Reference Standard

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate, British Pharmacopoeia (BP) Reference Standard

BP852

Salbutamol impurity B, British Pharmacopoeia (BP) Reference Standard

BP704

Salbutamol ketone impurity, British Pharmacopoeia (BP) Reference Standard

PHR2106

4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-methylphenol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9050

4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9071

4-[2-[Benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol, certified reference material, TraceCERT^®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

1012564

PHR2332

Methyl5-[2-[benzyl(tert-butyl)amino]acetyl]-2-hydroxybenzoate hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

GHS08,GHS07

Palavra indicadora

Warning

Frases de perigo

H317,H351,H361fd

Declarações de precaução

P202 - P261 - P272 - P280 - P302 + P352 - P308 + P313

Classificações de perigo

Carc. 2 - Repr. 2 - Skin Sens. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Helgo Magnussen et al.

The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)

Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.

Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial.

Todd A Florin et al.

JAMA pediatrics, 168(7), 664-670 (2014-05-28)

Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no effective therapies available. Current evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronchiolitis. To determine whether nebulized

Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial.

Susan Wu et al.

JAMA pediatrics, 168(7), 657-663 (2014-05-28)

Bronchiolitis is one of the most common and costly respiratory diseases in infants and young children. Previous studies have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency department (ED) setting is unclear. To compare

Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.

Dwight D Koeberl et al.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2171-2176 (2014-01-21)

Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased

Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.

B Padhukasahasram et al.

The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)

Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was

Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica